Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting
May 26 2017 - 7:05AM
Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that the Aduro
management team will host an investor event with special guest
speaker Jason J. Luke, M.D., FACP, Assistant Professor of Medicine
at the University of Chicago and a principal investigator for the
Phase 1 dose-escalation trial of ADU-S100 in patients with
advanced/metastatic solid tumors or lymphomas. This event will take
place in conjunction with the 2017 American Society of Clinical
Oncology (ASCO) Annual Meeting in Chicago, IL on Saturday June 3,
2017, at 6:00 a.m. Central Time.
Dr. Luke is a clinical investigator and a medical
oncologist whose research focuses on translational therapeutic
advances for melanoma and early phase drug development,
particularly immunotherapy.
To access the live webcast and subsequent archived
recording of this and other company presentations, please visit the
investor section of Aduro's website at www.aduro.com.
About Aduro Aduro Biotech, Inc. is
an immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
mesothelioma, ovarian, lung and prostate cancers. Additionally, a
personalized form of LADD, or pLADD, is being developed utilizing
tumor neoantigens that are specific to an individual patient’s
tumor. Aduro's STING Pathway Activator platform is designed to
activate the STING receptor in immune cells, resulting in a potent
tumor-specific immune response. ADU-S100 is the first STING Pathway
Activator compound to enter the clinic and is currently being
evaluated in a Phase 1 study in patients with cutaneously
accessible metastatic solid tumors or lymphomas. Aduro’s B-select
monoclonal antibody platform includes a number of immune modulating
assets in research and preclinical development. Aduro is
collaborating with leading global pharmaceutical companies to
expand its products and technology platforms. For more information,
please visit www.aduro.com.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Susan Lehner
510 809 2137
press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Sep 2023 to Sep 2024